L-AmB standard dose
Phase 3Small molecule
L-AmB standard dose is one of 9 small molecule programs targeting Histoplasmosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Histoplasmosis
#DrugCompanyPhaseTrials
1Sporanox
SSebela Pharmaceuticals Development LLC
Phase 3
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Visudyne
BBausch Health Americas, Inc.
Phase 2
Eylea
RegeneronPhase 1
Lucentis
RochePhase 1
L-AmB standard dose
FFederal University of Health Science of Porto Alegre
Phase 3
Macugen
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-AmB standard dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details